Pixantrone: A B-cell-depleting immunosuppressant for multiple sclerosis patients with active disease

Multiple Sclerosis Journal

Volumn 22, Issue 6, 2016, Pages 817-821

  Gonsette, Richard ^a   Debouverie, Marc ^b   Sindic, Christian ^c   Ferré, Jean Christophe ^d   Edan, Gilles ^d  

^a National Center for Multiple Sclerosis   (Belgium)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d RENNES UNIVERSITY HOSPITAL   (France)

Author keywords

Active disease; B cell depletion; Diseasemodifying therapies; Immunosuppression; Multiple sclerosis; Pixantrone

Indexed keywords

ANTIEMETIC AGENT; CD19 ANTIGEN; GADOLINIUM; PIXANTRONE;

ADULT; ARTICLE; ASTHENIA; CD3+ T LYMPHOCYTE; CD4 CD8 RATIO; CLINICAL ARTICLE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ECHOCARDIOGRAPHY; EOSINOPHIL COUNT; EXPANDED DISABILITY STATUS SCALE; FEMALE; HAIR LOSS; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOCYTE COUNT; LYMPHOCYTOPENIA; MALE; MENSTRUAL IRREGULARITY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RECURRENCE RISK; THROMBOCYTE COUNT; VOMITING;

EID: 85016170512     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458515601902     Document Type: Article

References (15)

1. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997; 62: 112-118.
2. Hartung HP, Gonsette R, König N, et al. Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360: 2018-2025.
3. Le Page E, Leray E, Taurin G, et al. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: Treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry 2008; 79: 52-56.
4. Edan G, Comi G, Le Page E, et al. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: A 3-year randomised trial. J Neurol Neurosurg Psychiatry 2011; 82: 1344-1350.
5. Le Page E, Leray E and Edan G. Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: A 5-year prospective study. Mult Scler 2011; 1: 867-875.
6. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005; 58: 840-846.
7. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology 2014; 83: 278-286.
8. Salvatorelli E, Menna P, Paz OG, et al. The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: Insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients. J Pharmacol Exp Ther 2013; 344: 467-478.
9. Cavalletti E, Crippa L, Mainardi P, et al. Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: Comparative studies against doxorubicin and mitoxantrone. Invest New Drugs 2007; 25: 187-195.
10. Longo M, Della Torre P, Allievi, et al. Tolerability and toxicological profile of pixantrone (Pixuvri®) in juvenile mice. Comparative study with doxorubicin. Reprod Toxicol 2014; 46: 20-30.
11. Péan E, Flores B, Hudson I, et al. The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: Summary of the scientific assessment of the committee for medicinal products for human use. Oncologist 2013; 18: 625-633.
12. Paul F, Dörr J, Würfel J, et al. Early mitoxantroneinduced cardiotoxicity in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2007; 78: 198-200.
13. De Isabella P, Palumbo M, Sissi C, et al. Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza-and 2-aza-oxide-anthracenedione derivatives. Mol Pharmacol 1995; 48: 30-38.
14. Duddy M, Niino M, Adatia F, et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007; 178: 6092-6099.
15. Neuhaus O, Kieseier BC and Hartung HP. Therapeutic role of mitoxantrone in multiple sclerosis. Pharmacol Ther 2006; 109: 198-209.